EcoR1 Capital’s Iovance Biotherapeutics IOVA Stock Holding History

EcoR1 Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-213,647	Closed	-$5.91M	–	57
2019 Q4	$5.91M	Buy	+213,647	New	+$4.86M	0.53%	33

Other funds holding IOVA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital's IOVA Position: Q1 2020 in Review

EcoR1 Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2020, closing a stake of 213,647 shares — an estimated $5.91M sold.

EcoR1 Capital first reported a position in IOVA in Q4 2019 and held it in 1 quarter. The position peaked at $5.91M in Q4 2019. 219 funds tracked by Wall St. Rank hold IOVA as of Q1 2020.

EcoR1 Capital reported no remaining Iovance Biotherapeutics position as of Q1 2020 after selling out during the quarter.
EcoR1 Capital sold 213,647 Iovance Biotherapeutics shares in Q1 2020, an estimated $5.91M.
EcoR1 Capital first reported a position in Iovance Biotherapeutics in Q4 2019 and held it in 1 quarter.
EcoR1 Capital's Iovance Biotherapeutics position peaked at $5.91M in Q4 2019.
219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2020.

Based on EcoR1 Capital's 13F filing for Q1 2020, filed 15 May 2020.